Efficacy and Safety of The Biosimilar Denosumab Candidate (Arylia) Compared to the Reference Product (Prolia®) in Postmenopausal Osteoporosis: A Phase Iii, Randomized, Two-Armed, Double-Blind, Parallel, Active-Controlled, and Noninferiority Clinical Trial Publisher Pubmed



Jamshidi A¹ ; Vojdanian M² ; Soroush M^{3, 15} ; Akbarian M² ; Aghaei M⁴ ; Hajiabbasi A⁵ ; Mirfeizi Z⁶ ; Khabbazi A⁷ ; Alishiri G⁸ ; Haghighi A⁹ ; Salimzadeh A¹⁰ ; Karimzadeh H¹¹ ; Shirani F¹² ; Fard MRH¹³ Show All Authors Show Affiliations
Source: Arthritis Research and Therapy Published:2022

Abstract

Background/objective: Osteoporosis is a global health concern with an increasing prevalence worldwide. Denosumab is an antiresoptive agent that has been demonstrated to be effective and safe in osteoporotic patients. This study aimed to compare the efficacy and safety of the biosimilar denosumab candidate (Arylia) to the originator product (Prolia®) in postmenopausal osteoporotic patients. Methods: In this randomized, double-blind, active-controlled, noninferiority trial, postmenopausal osteoporotic patients received 60 mg of subcutaneous Arylia or Prolia® at months 0, 6, and 12 and were followed up for 18 months. The primary endpoint was the noninferiority of the biosimilar product to the reference product in the percentage change of bone mineral density (BMD) in 18 months at the lumbar spine (L1-L4), total hip, and femoral neck. The secondary endpoints were safety assessment, the incidence of new vertebral fractures, and the trend of bone turnover markers (BTMs). Results: A total of 190 patients were randomized to receive either biosimilar (n = 95) or reference (n = 95) denosumab. In the per-protocol (PP) analysis, the lower limits of the 95% two-sided confidence intervals of the difference between Arylia and Prolia® in increasing BMD were greater than the predetermined noninferiority margin of − 1.78 at the lumbar spine, total hip, and femoral neck sites (mean differences [95% CIs] of 0.39 [− 1.34 to 2.11], 0.04 [− 1.61 to 1.69], and 0.41 [− 1.58 to 2.40], respectively). The two products were also comparable in terms of safety, new vertebral fractures, and trend of BTMs. Conclusion: The efficacy of the biosimilar denosumab was shown to be noninferior to that of the reference denosumab, with a comparable safety profile at 18 months. Trial registration: ClinicalTrials.gov, NCT03293108; Registration date: 2017–09-19. © 2022, The Author(s).